Draupnir Bio ApS: Financial statements 2019
CVR: 38546880
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -15,909,546 and a net result of DKK -15,194,060 compared with DKK -2,117,554 the year before. Equity in the 2019 report amounted to DKK 51,974,272. The solvency ratio was 97.3%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -15,909,546
- Profit/Loss
- DKK -15,194,060
- Equity
- DKK 51,974,272
- Total Assets
- DKK 53,395,262
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -15.9 mio. | -15.2 mio. | 52 mio. | 2 |
| 2018 | - | -1.8 mio. | -2.1 mio. | -1.8 mio. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of October 23, 2019, Simon Glerup Pedersen has joined the board of directors of Draupnir Bio ApS.
As of October 23, 2019, Fiona MacLaughlin has joined the board of directors of Draupnir Bio ApS.
As of October 23, 2019, Stefan Emanuel Luzi has joined the board of directors of Draupnir Bio ApS.
As of October 23, 2019, Peter Hans Andreas Seeberger has left the board of directors of Draupnir Bio ApS.
Draupnir Bio ApS has published its annual report for 2018. Gross profit came to DKK -1,779,479, and the net result was DKK -2,117,554.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The board consists of Eva-Lotta Coulter (chair), Emmanuelle Coutanceau, Ivan Burkov and Robert Andrew Donald Scott. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. According to the 2025 annual report, the company had an average of 9 employees. Equity in the 2025 report amounted to DKK 15,256,000.